Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
Feb 9, 2022Sunovion and Otsuka Initiate Phase 3 Clinical Development of Non-Racemic Amisulpride for the Treatment of People with Bipolar Depression
MARLBOROUGH, Mass. & PRINCETON, N.J., February 09, 2022 08:00 am (BUSINESS WIRE) — Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc....
Oct 8, 2021Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia•RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia
CAMBRIDGE, Mass. & BASEL, Switzerland, October 8, 2021 (GLOBE NEWSWIRE) – Enzyvant today announced the U.S. Food and Drug Administration (FDA) approval of RETHYMIC® (allogeneic processed thymus...
Sep 30, 2021Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration-Companies to advance four promising Sunovion compounds for people living with serious neuropsychiatric conditions-
MARLBOROUGH, Mass. & OSAKA, Japan & TOKYO, Japan--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion),its parent company Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) and...
Jun 29, 2021Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive Bladder•Co-promotion extends sales and market access efforts to reach primary care physicians who treat OAB patients
IRVINE, Calif. & BASEL, Switzerland & MARLBOROUGH, Mass., June 29, 2021 at 9:00 AM EDT (BUSINESS WIRE)– Urovant Sciences, Inc. and Sunovion Pharmaceuticals Inc. today announced the launch of...
May 26, 2021Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids•In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL reductions of 82.0% and 84.3% from baseline
BASEL, Switzerland and NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has...
Apr 12, 2021Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet•SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 years
BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3...
Apr 2, 2021Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)Nationwide availability gives healthcare providers and patients a new treatment option
IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)– Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today...
Mar 29, 2021Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for RELUGOLIX for the Treatment of Advanced Prostate Cancer•If approved, relugolix would be the first and only oral androgen deprivation therapy for advanced prostate cancer in Europe
BASEL, Switzerland, March 29, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines...
Feb 17, 2021Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids•LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline
NEW YORK, LONDON, February 17, 2021 (GLOBE NEWSWIRE) — Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of...
Feb 16, 2021•Six women reflect on their period experiences and journeys to self-advocacy in new video series
RED BANK, N.J. and BASEL, Switzerland, Feb. 16, 2021 (GLOBE NEWSWIRE) — HealthyWomen, the nation’s leading independent, nonprofit health information source for women, and Myovant Sciences...